Acasti Pharma Inc
For the period ended Dec 31, 2023. Filed Feb 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 12, 2024
GRCE$1.87+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Balance Sheets
| December 31,2023 | March 31,2023 | |
|---|---|---|
| (Expressed in thousands except share data) | $ | $ |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 18,545 | 27,875 |
| Short-term investments | 6,569 | 15 |
| Receivables | 959 | 802 |
| Prepaid expenses | 811 | 598 |
| Total current assets | 26,884 | 29,290 |
| Operating lease right of use asset | 23 | 463 |
| Equipment | 12 | 104 |
| Intangible assets | 41,128 | 41,128 |
| Goodwill | 8,138 | 8,138 |
| Total assets | 76,185 | 79,123 |
| Liabilities and Shareholders’ equity | ||
| Current liabilities: | ||
| Trade and other payables | 1,746 | 3,336 |
| Operating lease liability | 24 | 75 |
| Total current liabilities | 1,770 | 3,411 |
| Derivative warrant liabilities | 3,332 | — |
| Operating lease liability | — | 410 |
| Deferred tax liability | 6,403 | 7,347 |
| Total liabilities | 11,505 | 11,168 |
| Commitments and contingencies (Note 12) | ||
| Shareholders’ equity: | ||
| Class A common shares, no par value per share; unlimited shares authorized as of December 31, 2023 and March 31, 2023; 9,399,404 and 7,435,533 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively | 261,038 | 258,294 |
| Class B, C, D and E common shares, no par value per share; unlimited shares authorized as of December 31, 2023 and March 31, 2023; none issued and outstanding | — | — |
| Additional paid-in capital | 17,633 | 13,965 |
| Accumulated other comprehensive loss | (6,038) | (6,038) |
| Accumulated deficit | (207,953) | (198,266) |
| Total shareholders' equity | 64,680 | 67,955 |
| Total liabilities and shareholders’ equity | 76,185 | 79,123 |
See accompanying notes to unaudited interim consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.